Loading market dashboard
Ryder System, Inc.
RIndustrialsNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Headwinds, including inflation, tariff-related tensions, and lingering supply-chain disruptions, hurt the Zacks Transportation - Equipment and Leasing industry. WAB, AER and R are likely to stand out.
TOKYO, June 4, 2026 - (JCN Newswire) - INPEX CORPORATION (INPEX), Osaka Gas Co., Ltd. (Osaka Gas), and Mitsubishi Heavy Industries, Ltd. (MHI) today started ope
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) CEO John Diez to address the Wells Fargo 16th Industrials & Materials Conference. Who: Ryder System, Inc. CEO John Diez What: Wells Fargo 16th Industrials & Materials Conference When: Wednesday, June 10, 2026 Time: 11:00 a.m. Central Time Webcast: To access the live webcast, visit Ryder - Wells Fargo 16th Industrials & Materials Conference. About Ryder System, Inc. Ryder System, Inc. (NYSE: R) is a nearly $13 billion leading pro.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto®.
VANCOUVER, BC / ACCESS Newswire / May 29, 2026 / Core Critical Metals Corp. ("CCMC" or the "Company") (TSXV:CCMC)(OTCQB:CCMCF) (WKN: A41G8G), a North American mineral acquisition and exploration company, is pleased to announce that its common shares have been approved for listing on the OTCQB® Venture Market, operated by OTC Markets Group Inc. The Company's shares now trade on the OTCQB under the ticker symbol "CCMCF". In addition, the Company is pleased to confirm that its common shares have achieved Depository Trust Company ("DTC") eligibility, greatly facilitating the electronic clearing and settlement of its shares in the United States.
Third quarter sales reflect the impact of the continued changes in the global geopolitical landscape that has temporarily impacted outbound shipments from the USA to the Middle East distribution partners Third quarter sales and year-to-date sales growth of Dream Water® Canada E-commerce of 16% and 13% respectively offset by a decline in Dream Water® Canada Retail of 15% and 6% respectively compared to same periods last year Third quarter sales and year-to-date sales growth of LivRelief™ E-commerce of 60% and 32% respectively offset by a decline in LivRelief™ Retail of 30% and 27% respectively compared to same periods last year Vancouver, British Columbia--(Newsfile Corp. - May 29, 2026) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce its financial and operating results for the three and nine months ended March 31, 2026. The Delivra Health portfolio features innovative brands Dream Water® and LivRelief™, which deliver relief from common health issues such as sleeplessness, chronic pain and anxiety.
Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's unaudited interim consolidated financial statements for the three-month period ended March 31st, 2026 ("Financial Statements"). Theralase® will be hosting a conference call on June 9 th at 11:00 am ET, which will include a presentation of the financial and operational results for the quarter ended March 31st, 2026.
R pairs veteran-focused hiring with rising shareholder returns as earnings estimates climb and shares outperform.
UPPSALA, SE / ACCESS Newswire / May 28, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announced new data published in the European Journal of Cancer showing that DiviTumTKa can capture early, treatment-specific biological response in patients with endocrine-resistant HR+/HER2− metastatic breast cancer. The analysis included 555 patients from the phase III GEICAM/2013-02 PEARL trial and used Biovica's FDA 510(k)-cleared DiviTum TKa assay.
VANCOUVER, BC / ACCESS Newswire / May 27, 2026 / Totec Resources Ltd. ("Totec" or the "Company") (TSXV:TOTC)(OTCQB:TTCRF)(FSE:U0Z0), a leading resource company focused on critical metals and supporting the North American supply chain, is pleased to announce that its common shares have been approved for listing on the OTCQB® Venture Market, operated by OTC Markets Group Inc. The Company's shares are expected to commence trading on the OTCQB on May 28, 2026 under the ticker symbol "TTCRF".
The framework centers on site speed, server response, and technical reliability as AI retrieval becomes a filter for citation and discovery. Memphis, Tennessee--(Newsfile Corp. - May 27, 2026) - Leading digital marketing agency HigherVisibility, introduced an updated version of its Targeted Growth System (TGS), a proprietary methodology used across the agency's SEO, PPC, link building, eCommerce SEO, website design, and franchise SEO services.
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) has been recognized as a 3 Star Employer in the 2026 VETS Indexes Employer Awards, underscoring the company's long‑standing commitment to recruiting, hiring, retaining, developing, and supporting veterans and the military‑connected community. This represents Ryder's second time receiving this honor, following its 2024 designation as a VETS Indexes Recognized Employer. “Ryder is proud to employ so many members of the veteran community and to r.
Adopted in Fujitsu's next-generation processor, FUJITSU-MONAKAKAWASAKI, Japan, May 26, 2026 - (JCN Newswire) - Fujitsu today announced that its invention for im
New York, New York--(Newsfile Corp. - May 25, 2026) - KottonSpa™, a Texas-founded newborn brand that launched in March, introduced a collection of newborn essentials crafted entirely from 100% American-grown SUPIMA® cotton - widely regarded as the world's finest cottons and representing less than 1% of global cotton production. The collection includes SUPIMA® baby accessories, skin-first apparel, and occasion-ready pieces designed for newborns and toddlers ages 0–4 years.
BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by three the historical single agent activity of 8% in KEYNOTE-100 (2019) 56% disease control rate (DCR) in the combination arm, including multiple durable responses extending beyond 10 months with patients still on treatment The treatment exhibits a very favorable safety profile, and, in contrast to chemotherapy-based regimens, result in very low rates of safety-related treatment discontinuations A preliminary median progression-free survival (mPFS) of 10.3 months in the combination arm, based on early PFS analysis Activity observed across both high-grade serous and clear cell ovarian cancer subtypes Demonstrated robust Treg depletion, reprogramming of myeloid cells, and CD8+ T-cell activation, supporting BI-1808's differentiated mechanism and combination synergy with pembrolizumab Cohort expansion is underway, focusing on high-grade serous and clear cell subtypes, with another data readout expected in H2 2026 LUND, SE / ACCESS Newswire / May 21, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced highly promising early data from its ongoing Phase 2a clinical trial evaluating BI-1808, its monoclonal antibody targeting TNFR2, in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of heavily pretreated patients with advanced ovarian cancer.
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering") of 19,166,667 units ("Units") of the Company at a price of C$0.24 per Unit ("Offering Price") for gross proceeds of C$4,600,000; including, the full exercise of the over-allotment option. The Brokered Offering was led by Research Capital Corporation as sole agent and sole bookrunner ("Agent").
EY US celebrates ambitious entrepreneurs shaping the future of business Los Angeles, California--(Newsfile Corp. - May 19, 2026) - Vera Quinn, CEO of Cydcor, has been named a finalist for the Entrepreneur Of The Year 2026 Greater Los Angeles Award by Ernst & Young LLP (EY US). Now in its 41st year, the Entrepreneur Of The Year program celebrates the bold leaders who disrupt markets through the world's most ground-breaking companies, revolutionizing industries and uplifting communities.
Brisbane, Queensland, Australia--(Newsfile Corp. - May 19, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce the signing of a global distribution agreement with Curran International for THERMAL-XR® and for exclusive application services for the product oil and gas/LNG industry. Curran International is a global leader in providing heat transfer technologies to some of the world's largest oil and gas companies.
LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented at the 56th Annual Scientific Meeting of the ANZSNM, held in Canberra on 15-17 May 2026. The presentation provided an overview of the study evaluating the radiopharmaceutical drug candidate ¹⁷⁷Lu-SN201 in patients with advanced solid tumors, including case studies showing visible tumor uptake of ¹⁷⁷Lu-SN201 in two individuals with different head and neck cancers.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TORONTO, ON / ACCESS Newswire / May 13, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the relaunch of Canada's Top 40 Under 40® Award Program, renewing its commitment to recognizing the country's most outstanding young leaders. Caldwell is pleased to be working with Presenting Partner Tourmaline Oil Corp., National Sponsor Deloitte Canada, Travel Sponsor Air Canada, Media Sponsor Financial Post, Event Sponsor Ewing Morris & Co., and Referencing Sponsor Inline Reference Check.
~ First Quarter 2026 Revenue of $1.4 Million, an Increase of Approximately 90% Compared to Prior Year ~ ~ First Quarter Gross Profit of $0.9 Million, an Increase of Approximately 193% Compared to Prior Year ~ ~ Gross Margin Expanded Approximately 24 Percentage Points Year-Over-Year to 68.5% ~ ~ Closed $4.3 Million Senior Convertible Note Private Placement to Fund Commercial Expansion and Product Development ~ ~ Subsequent to Quarter End The Company Opened a new Center of Excellence Training Center in Tampa, FL, Along with Expansion of the Company's Sales Leadership Throughout the Eastern Region~ LOS GATOS, CA / ACCESS Newswire / May 12, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today reported financial results for the first quarter ended March 31, 2026. Financial Results and Business Updates First Quarter 2026 Results: First quarter revenue of $1.4 million, an increase of approximately 90% compared to $0.7 million in the first quarter of 2025.
Ryder System, Inc. (R) Presents at Bank of America 33rd Annual Industrials, Transportation and Airlines Key Leaders Conference Transcript
40% objective response rate ( ORR) as single agent in heavily pre - treated patients with advanced Cutaneous T-Cell Lymphoma (CTCL) Durable responses observed, including a complete response lasting over two years and ongoing 50% ORR in combination with KEYTRUDA® (pembrolizumab) Targeting TNFR2 drove robust immune activation, with depletion of regulatory T cells and increased CD8+ T cell infiltration in skin lesions Early immune - related skin reactions - "flares"- correlated with biological activity and immune remodeling Favorable safety profile with mostly mild to moderate treatment - related adverse events LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that new clinical data from its ongoing Phase 2a trial evaluating BI-1808, its novel anti-TNFR2 monoclonal antibody, in patients with advanced CTCL will be presented at the upcoming European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden. The data underscore BI-1808's potential as both a single agent and combination therapy in this difficult-to-treat cancer with limited therapeutic options.
LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden. Poster Presentation Title: Targeting resistance to rituximab through FcγRIIB (CD32B) blockade: BI-1206 + rituximab + acalabrutinib shows powerful activity in R/R NHL Presenter: Dr. Laura Fogliatto, Hospital de Clínicas de Porto Alegre, Brazil Session Date/Time: Friday, June 12, 6:45 pm-7:45 pm CEST (12:45 pm-1:45 pm EDT) Location: EHA2026 Congress, Stockholm The presentation will summarize emerging efficacy and safety observations and mechanistic insights from the ongoing Phase 1/2 study (NCT03571568) evaluating BI-1206 in combination with rituximab and Calquence® (acalabrutinib) in patients with relapsed or refractory NHL, including follicular lymphoma.
~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Taiwan Intellectual Property Office issued a patent covering Ensysce's MPAR® (Multi-Pill Abuse Resistance) technology. The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof", includes both composition-of-matter and method-of-use claims that strengthen Ensysce's intellectual property estate for its unique overdose protection platform.
MALMÖ, SE / ACCESS Newswire / May 12, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today published its Interim Report Q1 for 2026 (January - March), which is now available on the company's website: Financial Reports - ASCELIA KEY EVENTS IN Q1 2026 Abstract with Orviglance data has been accepted for oral presentation at the annual radiology congress ESGAR 2026 Management changes: Anton Hansson starts as CFO, while Julie Waras Brogren leaves her position as Deputy CEO KEY EVENTS AFTER THE PERIOD Ascelia Pharma completes directed share issue of SEK 20 million before transaction costs FINANCIAL SUMMARY Q1 (Jan-Mar) 2026 Operating result of SEK -17.2M (SEK -20.3M) Earnings per share of SEK -0.13 (SEK -0.23) Cash flow from operations of SEK -15.9M (SEK -16.9M) Liquid assets and marketable securities of SEK 33.9M (SEK 57.3M) "Orviglance® is on track for approval on the July 3 PDUFA date. FDA's review of our New Drug Application (NDA) progressed as planned during the quarter, and we remain fully engaged in a constructive, transparent dialogue with the agency as we approach the final month of the review.
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Agent") to act as the sole agent and sole bookrunner on a commercially reasonable "best efforts" agency basis for a brokered private placement offering ("Offering") of units of the Company ("Units") at a price of C$0.24 per Unit, to raise a minimum of C$3,000,000 and up to a maximum of C$4,000,000 in aggregate gross proceeds. Each Unit will consist of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant").
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) Chief Executive Officer John Diez will present a company update at the 2026 Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference. Who: Ryder System, Inc. Chief Executive Officer John Diez What: Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference When: Tuesday, May 12, 2026 Time: 11:05 a.m. Eastern Time Webcast: To access the link to the live webcast, visit: Ryder.
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period ended December 31st, 2025 ("Financial Statements"). Theralase® will be hosting a conference call on May 12 th at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal year ending December 31st, 2025.
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - Gelum Resources Ltd. (CSE: GMR) (OTCQB: GMRCF) ("Gelum" or the "Company") reports that the Company's common shares have been re-approved and admitted for trading on the OTCQB Venture Market under the symbol GMRCF commencing May 4, 2026.
New York, New York--(Newsfile Corp. - May 1, 2026) - AminoQuest Labs® (https://aminoquestlabs.com), a U.S.-based supplier of research peptides, today announced the official launch of its new online platform along with expanded capabilities to support laboratories and research professionals nationwide. The newly launched website provides streamlined access to research-grade peptide compounds, enhanced product documentation, and improved ordering functionality designed for scientific and laboratory use.
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder declares quarterly cash dividend.
R's upbeat used-vehicle sales, contractual growth and disciplined operations --- plus dividends and buybacks ---- boost its outlook as freight recovers.
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder authorizes new discretionary plan to repurchase shares.
Prospective Study Conducted at Holy Spirit Hospital in Mumbai Reports 95% Vein Occlusion Rate at 30 Prospective Study Conducted at Holy Spirit Hospital in Mumbai Reports 95% Vein Occlusion Rate at 30
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ryder (R) possesses solid growth attributes, which could help it handily outperform the market.
Does Ryder (R) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Quality of Life Scores Presented; Additional Presentations Scheduled in Early May Details to be Discussed During Fireside Chat on April 29, 2026 at 4:30 pm ET White Bear Lake, Minnesota--(Newsfile Corp. - April 28, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the first podium presentations of clinical data from the first stage of its pivotal clinical study of the investigational Acclaim® cochlear implant, a first-of-its-kind, fully implanted cochlear implant system. The Company will host a Fireside Chat with Dr. Theodore McRackan, MD, MSCR and Dr. Elizabeth Camposeo, AuD from the Medical University of South Carolina (MUSC) on Wednesday April 29, 2026 at 4:30 pm ET to review the data and its clinical implications.
New ELISA sphingotest® penKid® enables widespread measurement of the kidney function biomarker Proenkephalin 119-159 (penKid) using standard laboratory equipment. Only available test to match SphingoTec's reference chemiluminescence assay, developed with patented high-sensitivity technology to provide consistent results across platforms.
R's Q1 EPS beat estimates and rose 3.3% even as revenue slipped, with management lifting its 2026 adjusted EPS and revenue growth outlook.
Ryder System (NYSE: R) reported first-quarter 2026 results that management said exceeded internal expectations, driven largely by stronger-than-anticipated used vehicle sales in its Fleet Management Solutions business. On the company's earnings call, Chief Executive Officer John J. Diez said the quarter reflected "the strength of our contractual portfolio and resiliency of our transformed model" during what
Ryder System, Inc. (R) Q1 2026 Earnings Call Transcript
Ryder System has improved business resilience via a shift to leasing and conservative depreciation, supporting higher quality earnings and a 65% stock rally over the past year. Q1 results showed $2.54 EPS on flat $3.1 billion revenue, with segment margin expansion in Fleet Management and stable used vehicle pricing insulating performance. R reaffirmed FY guidance: 3% operating revenue growth, $14.05–$14.80 EPS, and $700–$800 million in free cash flow, targeting long-term ROE in the low-20% range.
While the top- and bottom-line numbers for Ryder (R) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ryder (R) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $2.29 per share. This compares to earnings of $2.46 per share a year ago.
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) reported results for the three months ended March 31 as follows: Earnings Before Taxes Earnings Diluted Earnings Per Share (In millions, except EPS) 2026 2025 2026 2025 2026 2025 Continuing operations (GAAP) $ 118 134 $ 93 98 $ 2.34 2.29 Comparable (non-GAAP) $ 128 142 $ 101 106 $ 2.54 2.46 Total and operating revenue for the three months ended March 31 were as follows: Total Revenue Operating.
SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced the successful completion of the first clinical procedure utilizing the 510(k)-cleared Velocity Alpha MR High Speed Surgical Drill System. Utilized in a four-trajectory clinical trial procedure, the system highlights its scalability and potential to support a broader range of programs within the Company's partnered biologics portfolio.
BioInvent International (STO:BINV) - BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when combined with PD-1 blockade LUND, SE / ACCESS Newswire / April 21, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that additional clinical data from its ongoing Phase 2a study evaluating BI-1808 in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in advanced ovarian cancer has been selected for a poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago May 29 - June 2, 2026.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Ryder (R), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) will return to the Advanced Clean Transportation (ACT) Expo, May 4–7 in Las Vegas, showcasing the company's industry expertise in next-generation logistics and vehicle technologies. This includes executive speaking sessions and an interactive booth featuring emission reduction technologies such as near-zero and zero-emission solutions for light‑duty vehicles and yard tractors. Ryder executives will participate in three ACT Expo sessions focus.
Brisbane, Queensland, Australia--(Newsfile Corp. - April 20, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to advise that GMG's patent for GMG's Graphene Engine Oil Additive, G® LUBRICANT, has now been granted for 20 years in the USA and allowed in China. This is in addition to the previously announced G® LUBRICANT patent accepted for the European region.
Ryder (R) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoption Renowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellence network Strengthens surgeon engagement and expands Regentis' European commercialization infrastructure HERZLIYA, IL / ACCESS Newswire / April 16, 2026 / Regentis Biomaterials Ltd.
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) is expanding its Southeast presence with the opening of a new 10,000-square‑foot full-service commercial truck rental and maintenance facility in Huntsville, Alabama. Located near Exit 7 off I-565 and seven miles from I-65, the facility at 28719 Old Highway 20 in Madison provides access to fleet, rental, and maintenance services in one of Alabama's fastest-growing industrial and logistics markets. Positioned near major automotive manufacturer.
On April 15, 2026, Ryder System Inc (R) shares fell 3.5% to a price of $212.05. This move comes within a 52-week price range of $130.16 to $230.39, highlighting
